articleTop 1% cited

Decitabine improves patient outcomes in myelodysplastic syndromes

Cancer · 2006 · Vol. 106(8) · pp. 1794–1803

Hagop M. Kantarjian✉(The University of Texas MD Anderson Cancer Center)Jean‐Pierre J. Issa(The University of Texas MD Anderson Cancer Center)C RosenfeldJohn M. Bennett(University of Rochester Medical Center)Maher Albitar(Quest Diagnostics (United States))John F. DiPersio(Washington University in St. Louis)Virginia M. Klimek(Memorial Sloan Kettering Cancer Center)James L. Slack(Roswell Park Comprehensive Cancer Center)Carlos de Castro Lozano(Duke Medical Center)Farhad Ravandi(University of Illinois Chicago)Richard E. Helmer(Regional Cancer Center)Lanlan Shen(The University of Texas MD Anderson Cancer Center)Stephen D. Nimer(Memorial Sloan Kettering Cancer Center)Richard D. LeavittAzra Raza(Rush University Medical Center)Hussain I. Saba(James A. Haley Veterans' Hospital)

View via DOI Publisher page

Abstract

Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further.

Acute Myeloid Leukemia Research Epigenetics and DNA Methylation Acute Lymphoblastic Leukemia researchDecitabineMedicineMyelodysplastic syndromesInternal medicineAzacitidineLeukemiaOncologyDNA methylationBone marrowGene

MeSH terms

DecitabineAcute DiseaseAgedAntimetabolites, AntineoplasticAzacitidineFemaleHumansLeukemia, MyeloidMaleMiddle AgedMyelodysplastic SyndromesPalliative CareQuality of LifeSurvival RateDisease Progression

Citations

1,506

FWCI

39.51

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents